Study of sugemalimab plus chemotherapy for NK/T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This study tests a new medicine called sugemalimab (an immunotherapy that helps your immune system fight cancer) combined with a chemotherapy regimen (PGemOx) for people with a rare type of lymphoma that has come back or not responded to previous treatment. The study could help you see if this combination works better than the placebo (inactive) plus the same chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called extranodal NK/T-cell lymphoma (often starts in the nose) that has come back or not responded to at least one prior treatment.
- You have at least one measurable area of lymphoma on scans (CT or PET).
- You are able to do your daily activities with some help (but not bedridden).
- Your overall health is good enough for your organs to handle the study treatment.
- You agree to provide a sample of your tumor tissue for review by the study center.
- You are not pregnant or breastfeeding, and you have not had other cancers within the last 5 years (except for some minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.